0.00
100.00%
-23.01
Harpoon Therapeutics Inc stock is currently priced at $0.00, with a 24-hour trading volume of 0.
It has seen a -100.00% decreased in the last 24 hours and a -100.00% declined in the past month.
The chart indicates a potential bearish trend, as the stock is below the $23.01 pivot point. If it approaches the $22.96 support level, significant changes may occur.
Previous Close:
$23.01
Open:
$0
24h Volume:
0
Market Cap:
$492.35M
Revenue:
$37.34M
Net Income/Loss:
$-30.50M
P/E Ratio:
0.00
EPS:
-11.8
Net Cash Flow:
$-69.50M
1W Performance:
-100.00%
1M Performance:
-100.00%
6M Performance:
-100.00%
1Y Performance:
-100.00%
Harpoon Therapeutics Inc Stock (HARP) Company Profile
Name
Harpoon Therapeutics Inc
Sector
Industry
Phone
650 443 7400
Address
131 Oyster Point Boulevard, Suite 300, South San Francisco, CA
Harpoon Therapeutics Inc Stock (HARP) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Jul-06-22 | Resumed | Canaccord Genuity | Buy |
Sep-28-21 | Upgrade | Citigroup | Neutral → Buy |
Jun-08-21 | Downgrade | Citigroup | Buy → Neutral |
Jun-07-21 | Downgrade | Wedbush | Outperform → Neutral |
May-28-21 | Initiated | Cantor Fitzgerald | Overweight |
May-10-21 | Initiated | Piper Sandler | Overweight |
Dec-23-20 | Resumed | H.C. Wainwright | Buy |
May-22-20 | Initiated | Piper Sandler | Overweight |
Feb-28-20 | Initiated | SunTrust | Buy |
Feb-03-20 | Initiated | H.C. Wainwright | Buy |
Nov-14-19 | Initiated | ROTH Capital | Buy |
May-24-19 | Resumed | Citigroup | Buy |
Apr-23-19 | Initiated | Robert W. Baird | Outperform |
Mar-05-19 | Initiated | Wedbush | Outperform |
View All
Harpoon Therapeutics Inc Stock (HARP) Latest News
Ocular Therapeutix (OCUL) Reports Q4 Loss, Misses Revenue Estimates
Zacks Investment Research
Analyst Scoreboard: 4 Ratings For Harpoon Therapeutics
Benzinga
Merck (MRK) Q4 Earnings Beat, Sales Miss, Upbeat '24 View
Zacks Investment Research
This 1 Bullish Move by Merck Could Drive Growth for Years to Come
The Motley Fool
Company News for Jan 9, 2024
Zacks Investment Research
Merck (MRK) to Strengthen Cancer Pipeline With Harpoon Buyout
Zacks Investment Research
Harpoon Therapeutics Inc Stock (HARP) Financials Data
Harpoon Therapeutics Inc (HARP) Revenue 2024
HARP reported a revenue (TTM) of $37.34 million for the quarter ending September 30, 2023, a +16.14% rise year-over-year.
Harpoon Therapeutics Inc (HARP) Net Income 2024
HARP net income (TTM) was -$30.50 million for the quarter ending September 30, 2023, a +56.96% increase year-over-year.
Harpoon Therapeutics Inc (HARP) Cash Flow 2024
HARP recorded a free cash flow (TTM) of -$69.50 million for the quarter ending September 30, 2023, a +21.02% increase year-over-year.
Harpoon Therapeutics Inc (HARP) Earnings per Share 2024
HARP earnings per share (TTM) was -$8.76 for the quarter ending September 30, 2023, a +59.48% growth year-over-year.
About Harpoon Therapeutics Inc
Harpoon Therapeutics, Inc., a clinical-stage immunotherapy company, engages in the development of a novel class of T cell engagers that harness the power of the body's immune system to treat patients suffering from cancer and other diseases in the United States. The company develops tri-specific T cell activating construct (TriTAC) product candidate, including HPN328, which is in Phase I/II clinical trials for the treatment of small cell lung cancer and other Delta-like canonical Notch ligand 3-expressing tumors; HPN217 that is in Phase I/II clinical trials for the treatment of multiple myeloma; and HPN536, which is in Phase I/IIa clinical trials for the treatment of ovarian and pancreatic cancer, and other mesothelin-expressing tumors. Its preclinical stage product is HPN601 for the treatment of multiple solid tumor indications. The company has a discovery collaboration and license agreement with AbbVie Biotechnology Ltd. to develop and commercialize products that incorporate its proprietary TriTAC platform technology together with soluble T cell receptors. Harpoon Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.
Cap:
|
Volume (24h):